secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001437749-25-029349
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement
--------------------------------------------------------------------------------

- PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
- Plasma EC50 of 37 ng/mL at 24h and 12 ng/mL at 168h shows sustained target engagement.
- Safety profile consistent with prior studies; no new safety signals identified.
- Planned Phase 2 doses expected to exceed 90% target coverage at trough with once-daily dosing.
- 12 healthy volunteers and 4 PrMS patients enrolled; trial met primary PK/RO correlation objectives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/0001437749-25-029349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/ctnm20250910_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer